News
13h
Clinical Trials Arena on MSNOcugen doses first subject in trial of modifier gene therapy candidateOcugen has dosed the first subject in its Phase II/III GARDian3 trial of modifier gene therapy candidate, OCU410ST ...
The Baloch Liberation Army (BLA) has claimed responsibility for a deadly bomb blast that killed a senior Pakistani Army ...
Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...
The Baloch Liberation Army has claimed responsibility for a bomb blast in Quetta that killed Major Anwar Kakar, a senior ...
George Mulligan, PhD, previews the FDA's ODAC meeting discussing the application of belantamab mafodotin-based combinations for the treatment of multiple myeloma.
A New York-based privately held real estate operator and investment management firm has purchased the Park Place student ...
The Baloch Liberation Army (BLA) has claimed responsibility for two attacks in Balochistan, killing 29 Pakistani soldiers. In ...
Balochistan's security situation took a dramatic turn this week, as both banned separatist groups, Balochistan Liberation ...
Police and government officials in southwestern Pakistan say that gunmen have opened fire on a passenger bus, killing at least three people and wounding seven others ...
The U.S. FDA has accepted a Biologics License Application (BLA) for BAT2506, a proposed biosimilar to Simponi (golimumab).
Pierre Fabre leads global development of tab-cel, an innovative therapy for EBV+ PTLD, with ongoing trials and potential FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results